Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04404361 · ClinicalTrials.gov registry record · Phase 2
PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer
A Phase 2 study, sponsored by CTI BioPharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT04404361: Clinical Trial Phase 2 study, sponsored by CTI BioPharma.
NCT04404361 is a Phase 2 study that was terminated before completion, run by CTI BioPharma. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04404361, a Phase 2 study, was terminated before completion, sponsored by CTI BioPharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pacritinib in hospitalized patients with severe COVID-19 with or without cancer.
Interventions
- DRUG Placebo
- DRUG Pacritinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2020-05-22 |
| Est. Completion | 2021-09-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04404361
The ClinicalTrials.gov registry entry for NCT04404361 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04404361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04404361 about?
NCT04404361 is a clinical study titled "PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer". This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pacritinib in hospitalized patients with severe COVID-19 with or without cancer.
What is the current status of trial NCT04404361?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2020-05-22. Estimated completion is 2021-09-21.
What interventions are being tested in trial NCT04404361?
The interventions under investigation include: Placebo (DRUG), Pacritinib (DRUG).
Who is sponsoring clinical trial NCT04404361?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.